肺炎鏈球菌疫苗市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024 年全球肺炎鏈球菌疫苗市場價值為 88 億美元，預計 2025 年至 2034 年期間的複合年成長率為 5.6%。推動這一成長的因素有幾個，包括肺炎球菌感染患病率的上升、公眾對疫苗接種重要性的認知的提高，以及政府在全球範圍內推廣免疫計劃的有利舉措。疫苗接種率的激增可以歸因於衛生當局加強實施強制疫苗接種計劃，特別是針對兒童和高風險族群。研發領域的不斷進步正在推動生產更有效、更具創新性的肺炎球菌疫苗，以滿足更廣泛的血清型需求。這些疫苗在降低肺炎鏈球菌引起的肺炎、腦膜炎和敗血症等危及生命的疾病的發生率方面發揮著至關重要的作用。

隨著各國政府優先考慮預防性醫療保健並將肺炎球菌疫苗納入常規免疫計劃，市場需求將大幅上升。人們對免疫功能低下者和老年族群的免疫接種日益關注，這為疫苗製造商創造了新的機會。此外，製藥公司正在與全球衛生組織密切合作，以擴大低收入地區獲得這些疫苗的機會，而肺炎球菌疾病在這些地區仍然是主要的公共衛生問題。疫苗研究資金的增加，加上開發涵蓋新興血清型的廣譜疫苗的舉措，預計將在未來十年進一步推動市場成長。

市場根據產品進行細分，各種肺炎球菌疫苗對預防嚴重細菌感染做出了重大貢獻。作為最廣泛使用的疫苗之一，預計將經歷顯著成長，預計複合年成長率為 5.8%，到 2034 年將產生 79 億美元的產值。該疫苗在預防多種肺炎鏈球菌血清型方面已被證實有效，因此得到了廣泛採用，尤其是在兒童和高風險成人群體中。該疫苗能夠提供長期免疫力，使其成為醫療保健提供者和政府疫苗接種運動的首選。該疫苗廣泛涵蓋肺炎、敗血症和腦膜炎等嚴重肺炎球菌疾病，在全球免疫計畫中的地位不斷加強。

肺炎鏈球菌疫苗市場主要分為兩種：結合疫苗和多醣體疫苗。結合疫苗在 2024 年佔據了市場主導地位，由於其能夠提供對肺炎球菌感染的長期保護，其市場價值達到 80 億美元。它們在預防肺炎球菌疾病方面非常有效，尤其是對五歲以下兒童，這推動了它們的需求不斷成長。此外，在成年人群中，特別是免疫系統較弱的人群和老年人中，應用範圍的擴大正在加速結合疫苗的採用。它們能夠減輕肺炎球菌疾病的整體負擔，因此成為常規免疫計劃的首選疫苗。

2024 年，美國肺炎鏈球菌疫苗市場產值達 37 億美元。美國老齡人口的增加是這一成長的主要驅動力，因為老年人由於免疫功能下降而面臨更高的感染肺炎球菌的風險。預防性醫療保健工作和全國範圍的疫苗接種計劃大大提高了疫苗接種率，確保了高危險群得到更好的保護。製藥公司和政府機構不斷提高疫苗覆蓋率，不斷努力開發更廣泛的肺炎鏈球菌血清型疫苗，進一步支持市場的長期擴張。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 肺炎鏈球菌疾病盛行率不斷上升
    • 政府免疫計劃和舉措
    • 人口老化日益加劇
    • 技術進步和新產品發布
  • 產業陷阱與挑戰
    • 疫苗成本高昂
    • 疫苗猶豫和認知度低
• 成長潛力分析
• 監管格局
• 技術格局
• 管道分析
• 未來市場趨勢
• 差距分析
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第5章：市場估計與預測：按產品，2021 年至 2034 年

• 主要趨勢
• 肺炎鏈球菌 (PCV10)
• 肺炎鏈球菌疫苗 23 (PPSV23)
• 前列腺癌疫苗 13 (PCV13)
• 沛兒 20 (PCV20)
• Synflorix（PCV10）
• 疫苗 (PCV15)
• 其他產品

第6章：市場估計與預測：依疫苗類型，2021 年至 2034 年

• 主要趨勢
• 肺炎鏈球菌結合疫苗（PCV）
• 肺炎鏈球菌多醣體疫苗（PPSV）

第7章：市場估計與預測：依年齡層，2021 年至 2034 年

• 主要趨勢
• 嬰兒和兒童（0-5歲）
• 成人（18-64歲）
• 老年人（65歲以上）

第8章：市場估計與預測：按配銷通路，2021 年至 2034 年

• 主要趨勢
• 醫院藥房
• 零售藥局
• 政府和公共衛生機構
• 電子商務

第9章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第10章：公司簡介

• Beijing Minhai Biological Technology
• Bio-Manguinhos/Fiocruz
• GlaxoSmithKline
• Merck & Co.
• Pfizer
• Serum Institute of India
• Walvax Biotechnology

The Global Pneumococcal Vaccine Market was valued at USD 8.8 billion in 2024 and is projected to grow at a CAGR of 5.6% between 2025 and 2034. Several factors are driving this growth, including the increasing prevalence of pneumococcal infections, rising public awareness about the importance of vaccination, and favorable government initiatives promoting immunization programs worldwide. The surge in vaccination rates can be attributed to growing efforts by healthcare authorities to implement mandatory vaccination schedules, particularly for children and high-risk populations. Ongoing advancements in research and development are leading to the production of more effective and innovative pneumococcal vaccines, catering to a wider range of serotypes. These vaccines play a crucial role in reducing the incidence of life-threatening conditions such as pneumonia, meningitis, and sepsis caused by Streptococcus pneumoniae.

As governments prioritize preventive healthcare and integrate pneumococcal vaccines into routine immunization schedules, market demand is set to rise significantly. The increasing focus on immunizing immunocompromised individuals and elderly populations is creating new opportunities for vaccine manufacturers. Furthermore, pharmaceutical companies are working closely with global health organizations to expand access to these vaccines in low-income regions, where pneumococcal diseases remain a major public health concern. Rising funding for vaccine research, coupled with initiatives to develop broad-spectrum vaccines that cover emerging serotypes, is expected to further boost market growth over the next decade.

The market is segmented based on product, with various pneumococcal vaccines contributing significantly to preventing severe bacterial infections. One of the most widely used vaccines is expected to experience notable growth, with a projected CAGR of 5.8%, generating USD 7.9 billion by 2034. Its proven efficacy in protecting against multiple Streptococcus pneumoniae serotypes has led to widespread adoption, especially in pediatric and high-risk adult populations. The vaccine's ability to provide long-term immunity makes it a preferred choice among healthcare providers and government vaccination campaigns. With its broad coverage against severe pneumococcal diseases, including pneumonia, sepsis, and meningitis, this vaccine continues to strengthen its position in global immunization programs.

The pneumococcal vaccine market is divided into two main types: conjugate vaccines and polysaccharide vaccines. Conjugate vaccines dominated the market in 2024, generating USD 8 billion due to their ability to offer long-lasting protection against pneumococcal infections. Their high effectiveness in preventing pneumococcal diseases, especially among children under five years old, has fueled their growing demand. Additionally, expanding applications among adult populations, particularly those with weakened immune systems and elderly individuals, are accelerating the adoption of conjugate vaccines. Their ability to reduce the overall burden of pneumococcal diseases has established them as the preferred choice for routine immunization schedules.

The U.S. pneumococcal vaccine market generated USD 3.7 billion in 2024. The rising elderly population in the country has been a key driver of this growth, as aging individuals face a higher risk of contracting pneumococcal infections due to declining immune function. Preventive healthcare efforts and nationwide vaccination programs have significantly increased vaccine uptake, ensuring better protection for high-risk populations. Pharmaceutical companies and government agencies continue to enhance vaccine coverage, with ongoing efforts to develop newer vaccines that target a broader range of pneumococcal serotypes, further supporting the market's long-term expansion.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of pneumococcal diseases
    • 3.2.1.2 Government immunization programs and initiatives
    • 3.2.1.3 Growing aging population
    • 3.2.1.4 Technological advancements and new product launches
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of vaccines
    • 3.2.2.2 Vaccine hesitancy and low awareness
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technology landscape
• 3.6 Pipeline analysis
• 3.7 Future market trends
• 3.8 Gap analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Pneumosil (PCV10)
• 5.3 Pneumovax 23 (PPSV23)
• 5.4 Prevnar 13 (PCV13)
• 5.5 Prevnar 20 (PCV20)
• 5.6 Synflorix (PCV10)
• 5.7 Vaxneuvance (PCV15)
• 5.8 Other products

Chapter 6 Market Estimates and Forecast, By Vaccine Type, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Pneumococcal conjugate vaccines (PCV)
• 6.3 Pneumococcal polysaccharide vaccines (PPSV)

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Infants and children (0–5 years)
• 7.3 Adults (18–64 years)
• 7.4 Elderly (65+ years)

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Government and public health agencies
• 8.5 E-commerce

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Beijing Minhai Biological Technology
• 10.2 Bio-Manguinhos/Fiocruz
• 10.3 GlaxoSmithKline
• 10.4 Merck & Co.
• 10.5 Pfizer
• 10.6 Serum Institute of India
• 10.7 Walvax Biotechnology